POTENTIAL LONG-TERM COST SAVINGS IN TREATMENT OF NAÏVE HIV-INFECTED PATIENTS WITH RILPIVIRINE/ TENOFOVIR/ EMTRICITABINE (SINGLE TABLET REGIMEN) IN THE RUSSIAN FEDERATION
Author(s)
Yagudina R, Kulikov A, Babiy VV
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
OBJECTIVES: To obtain long-term outcomes of using rilpivirine/tenofovir/emtricitabine (single tablet regimen) in treatment of naïve patients with HIV-1 RNA<100 000 copies/ml in the Russian Federation. METHODS: Cost analysis was based on the results of modeling the treatment of naïve HIV-infected patients with rilpivirine/tenofovir/emtricitabine (single tablet regimen)in the Russian Federation. RESULTS: The use of rilpivirine/tenofovir/emtricitabine (single tablet regimen) in the analyzed population, due to the better adherance and, as a result, better viral suppression, leads to the lower number of new HIV-infected persons. Therefore in life-time perspective the potential total costs savings for the whole population can be up to 8% (€ 1 116 010 172) and 6% (€ 841 581 441) compared to efavirenz + tenofovir/ emtricitabin (multi-pill regimen) and lopinavir + tenofovir/ emtricitabin (multi-pill regimen), respectively. CONCLUSIONS: Obtained results showed that better adherence on the treatment scheme rilpivirine/tenofovir/emtricitabine (single tablet regimen) among naïve patients with HIV-1 RNA<100 000 copies/ml can lead to potential significant long-term cost savings.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PIN31
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost/Cost of Illness/Resource Use Studies
Disease
Infectious Disease (non-vaccine)